Results 51 to 60 of about 9,727 (175)

Revisiting the Ethics of Urate‐Lowering Therapy Clinical Trials for Gout Management

Arthritis &Rheumatology, EarlyView.
Lisa K. Stamp, Dien Ho, Nicola Dalbeth
wiley   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath, Yousuf Alam, Afsana Mustak Mim, Maksuda Akter, Mohammad Abbas Gani, Khondaker Muhammad Khairul Alam, Md. Nur Alam   +6 more
wiley   +1 more source

Moving urate-lowering therapy in gout beyond guideline recommendations

Seminars in Arthritis and Rheumatism
The 'treat-to target serum urate strategy' when using urate-lowering therapy has been recommended by most specialist rheumatology societies for many years. An alternative "treat-to-avoid-symptoms" in gout has been suggested, albeit without a clear definition of what this means and how it might be implemented in clinical trials or clinical practice ...
Lisa K Stamp, Nicola Dalbeth
openaire   +2 more sources

Life‐Threatening Acute Tumor Lysis Syndrome With Multiorgan Failure Following First Cycle of Bendamustine–Rituximab in Chronic Lymphocytic Leukemia: A Case Report and Brief Review

Clinical Case Reports, Volume 14, Issue 4, April 2026.
Graphical timeline of the patient’s clinical course. The timeline illustrates key events in a patient with CLL who developed acute tumor lysis syndrome after the first cycle of bendamustine–rituximab, including TLS onset, multiorgan failure, hemodialysis, and full recovery. ABSTRACT Chronic lymphocytic leukemia is not uniformly low risk for tumor lysis
Malegna Temesgen Garuma, Kebede H. Begna, Tesfaye Belete Amare, Mengisteab Kassahun Desta, Derebe Shashigo Leilago, Humud Mohammed Ahmed   +5 more
wiley   +1 more source

Spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and asymptomatic hyperuricemia: comparison with healthy individuals with normal serum urate concentrations [PDF]

, 2016
Background To identify spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and people with asymptomatic hyperuricemia by comparing them to healthy individuals with normal serum urate ...
Dalbeth, N, Rome, K, Stewart, S, Vandal, AC   +3 more
core   +2 more sources

Potential Hypoglycemic, Hypolipidemic, and Hypouricemic Bioactive Components From Ampelopsis grossedentata Explored by Affinity Ultrafiltration With Three Enzyme Targets

eFood, Volume 7, Issue 2, April 2026.
By integrating bioaffinity ultrafiltration coupled with HPLC‐MS/MS, this study identified quercetin, myricetrin, dihydromyricetin, and taxifolin from Ampelopsis grossedentata as key inhibitors of α‐glucosidase, pancreatic lipase, and xanthine oxidase, highlighting the promising potential of A.
Siyang Mao, Chu Chu, Yanzhi Xiong, Mengjia Xu, Jian Yang, Mingquan Guo   +5 more
wiley   +1 more source

The independent association between parathyroid hormone levels and hyperuricemia: a national population study [PDF]

, 2012
Introduction: Increased frequencies of hyperuricemia and gout have been associated with primary hyperparathyroidism, and recent clinical trials of parathyroid hormone (PTH) have reported hyperuricemic adverse events. We evaluated the potential population
Choi, Hyon K, Choi, Jee Woong, Hui, Janet Y, Mount, David Bruce, Zhang, Yuqing, Zhu, Yanyan   +5 more
core   +1 more source

Nutritional Intervention With Perennial Ryegrass Modulates UA Metabolism in Goslings via Gut Microbiota–Antioxidant Pathway Modulation

Food Science &Nutrition, Volume 14, Issue 4, April 2026.
Perennial ryegrass supplementation modulates UA‐metabolism in goslings by reducing serum uric acid and creatinine through inhibition of hepatic xanthine oxidase and upregulation of urate transporters (ABCG2, OAT1, OAT3). It enhances antioxidant capacity via Nrf2 activation, improves intestinal barrier integrity, and enriches beneficial gut microbiota ...
Muhammad Arslan Asif, Zeshan Zulfiqar, Bahar E. Mustafa, Saira Saif, Zhichang Wang, Yalei Cui, Sun Hao, Liu Boshuai, Yinghua Shi   +8 more
wiley   +1 more source

Gouty Arthritic Microenvironment Triggered Core–Shell Microneedles for Hydrogen‐Enzyme Synergistic Gout Therapy

Small Structures, Volume 7, Issue 4, April 2026.
A core–shell structural MN patch (UAM@CS MN) based on a hydrogen‐enzyme synergistic therapeutic strategy to synchronize UA degradation and inflammation mitigation through a dual mechanism of action. Gouty arthritis (GA) is a chronic and progressive disease generally characterized by high articular uric acid (UA) levels and an inflammatory immune ...
Jiajun Miao, Jiamiao Jiang, Wenxin Xu, Haiying Liang, Lu Liu, Haixin Tan, Xiaoting Zhang, Yicheng Ye, Hanfeng Qin, Junbin Gao, Hao Tian, Fei Peng, Yunrui Hu, Shaoheng Zhang, Yingfeng Tu, Shuai Han   +15 more
wiley   +1 more source

Towards a cure for gout: A two‑stage treat‐to‐target strategy from inflammation control to structural remission

Rheumatology &Autoimmunity, EarlyView.
Jiani Liu, Ziwen Xu, Wenxi Cui, Man Lu, Qingqing Zhang, Wenxia Lin, Shixian Chen, Weikai Lin, Guichuan Lai, Meng Li, Juan Li   +10 more
wiley   +1 more source